Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 691 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 691 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $118.81, for a total transaction of $82,097.71. Following the sale, the chief financial officer now directly owns 72,709 shares in the company, valued at $8,638,556.29. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 23rd, Michael Burkes Brophy sold 496 shares of Natera stock. The shares were sold at an average price of $119.09, for a total transaction of $59,068.64.
• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The stock was sold at an average price of $120.76, for a total transaction of $73,422.08.
• On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $99.65, for a total value of $185,946.90.
• On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $102.77, for a total value of $127,229.26.

Natera Price Performance

Shares of NTRA stock traded down $1.50 during mid-day trading on Friday, hitting $117.67. 404,862 shares of the stock traded hands, compared to its average volume of 1,323,333. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $133.54. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The company’s 50-day simple moving average is $123.24 and its 200-day simple moving average is $111.24. The firm has a market cap of $14.55 billion, a price-to-earnings ratio of -48.03 and a beta of 1.53.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. During the same quarter last year, the business posted ($0.97) earnings per share. The company’s quarterly revenue was up 58.1% on a year-over-year basis. As a group, equities research analysts expect that Natera, Inc. will post -1.96 earnings per share for the current year.

Institutional Trading of Natera

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farallon Capital Management LLC increased its stake in Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares in the last quarter. First Light Asset Management LLC raised its holdings in shares of Natera by 295.9% during the first quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock valued at $60,063,000 after acquiring an additional 490,822 shares during the period. AQR Capital Management LLC raised its holdings in shares of Natera by 257.6% during the second quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock valued at $70,553,000 after acquiring an additional 469,327 shares during the period. Nikko Asset Management Americas Inc. purchased a new stake in shares of Natera in the 1st quarter valued at approximately $33,938,000. Finally, Sumitomo Mitsui Trust Holdings Inc. acquired a new position in Natera in the 1st quarter worth approximately $33,956,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on NTRA. TD Cowen increased their target price on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Stephens restated an “overweight” rating and set a $125.00 price target on shares of Natera in a research report on Friday, August 9th. Robert W. Baird lifted their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. The Goldman Sachs Group boosted their target price on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Friday. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.44.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.